The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid intensifying legal battles over pharmaceutical costs in the United States, a federal judge has blocked Colorado's attempt to impose a 70% price cap on Amgen's drug Enbrel. According to reports, the court's intervention halts a significant regulatory move that would have forced a drastic reduction in the drug's price. This ruling removes a localized but critical threat to the company's revenue stability at a time when state-level drug pricing boards are becoming more aggressive.
Enbrel remains a cornerstone of Amgen’s portfolio, generating approximately $3.7 billion in global sales in 2023 per the company's annual financial filings. In comparison to peers, while companies like AbbVie face similar pressures on blockbuster drugs like Humira, this court victory provides Amgen with a legal precedent to defend its pricing power. Financial analysis suggests that without such regulatory caps, the stock could be undervalued by as much as 45% based on projected cash flows.
In the markets, AMGN was priced at $374.15 (at close July 02, 2026), having traded within a range of $363.39 to $375.15 recently per market data. Traders should monitor for potential appeals from Colorado authorities and watch for similar legal challenges in other states, which could serve as further catalysts for the biotechnology sector's valuation.